文献速递其他结缔组织病

阿巴西普治疗早期弥漫性皮肤型系统性硬化症(ASSET)的安全性与疗效:2期双盲随机试验的开放标签延伸研究

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.
PubMed 文献 · Lancet Rheumatol · 2020-10-19

ASSET试验在加拿大、英国和美国22个中心纳入病程小于3年的弥漫性皮肤型系统性硬化症患者,双盲期12个月后继续开放标签阿巴西普125 mg皮下每周一次治疗6个月。开放标签延伸期间未发现新的安全信号,两组的改良Rodnan皮肤评分(mRSS)均较基线改善,数据支持进一步研究阿巴西普。

要点

  • 开放标签延伸6个月期间未发现阿巴西普新的安全信号
  • 阿巴西普组mRSS自基线改善12个月为-6.6,18个月为-9.8
  • 安慰剂组转为阿巴西普后mRSS自基线改善18个月为-6.3

核心结论

  • 开放标签延伸6个月期间未发现阿巴西普治疗弥漫性皮肤型系统性硬化症的新安全信号。
  • 两组患者转为开放标签治疗后均观察到mRSS及其他结局指标的临床有意义改善。
  • 这些数据支持对阿巴西普在弥漫性皮肤型系统性硬化症中开展进一步研究。

研究设计与样本

  • ASSET为在加拿大、英国和美国22个中心开展的双盲随机试验,纳入年龄≥18岁、首次非雷诺现象症状起病小于3年的弥漫性皮肤型系统性硬化症患者。
  • 双盲期12个月治疗(阿巴西普或安慰剂)完成后,患者接受进一步6个月开放标签阿巴西普125 mg皮下每周一次治疗。
  • 双盲试验主要终点为12个月时改良Rodnan皮肤评分(mRSS),开放标签延伸在18个月时重新评估;主要分析纳入完成双盲试验且接受至少一剂开放标签治疗的全部参与者(改良意向治疗)。
  • 双盲试验于2014年9月22日至2017年3月15日随机分配88例参与者,阿巴西普组44例、安慰剂组44例;每组32例完成6个月开放标签延伸。

主要发现

  • 阿巴西普组mRSS自基线平均改善12个月为-6.6(SD 6.4),开放标签延伸期间进一步改善,18个月为-9.8(8.1)。
  • 安慰剂组mRSS自基线平均改善12个月为-3.7(SD 7.6),18个月进一步改善为-6.3(9.3)。
  • 开放标签延伸期间,安慰剂-阿巴西普组9例患者发生感染(12起不良事件,1起严重不良事件),阿巴西普-阿巴西普组11例患者发生感染(14起不良事件,1起严重不良事件)。
  • 双盲期12个月内阿巴西普组发生2例死亡,与硬皮病肾危象相关;开放标签延伸期间未记录到死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis in a phase 2, double-blind randomised trial, with potential efficacy at 12 months. We report here the results of an open-label extension for 6 months. METHODS: Patients (aged ≥18 years) with diffuse cutaneous systemic sclerosis of less than 3 years' duration from their first non-Raynaud's symptom were enrolled into the ASSET trial (A Study of Subcutaneous Abatacept to Treat DiffuseCutaneous Systemic Sclerosis), which is a double-blind trial at 22 sites in Canada, the UK, and the USA. Aftercompletion of 12 months of treatment with either abatacept or placebo, patients received a further 6 months ofabatacept (125 mg subcutaneous every week) in an open-label extension. The primary endpoint of the double-blind trial was modified Rodnan Skin Score (mRSS) at 12 months, which was reassessed at 18 months in the open-label extension. The primary analysis included all participants who completed the double-blind trial and received at least one dose of open-label treatment (modified intention to treat). This trial is registered with ClinicalTrials.gov, NCT02161406. FINDINGS: Between Sept 22, 2014, and March 15, 2017, 88 participants were randomly allocated in the double-blind trial either abatacept (n=44) or placebo (44); 32 patients from each treatment group completed the 6-month open-labelextension. Among patients assigned abatacept, a mean improvement from baseline in mRSS was noted at 12 months (-6·6 [SD 6·4]), with further improvement seen during the open-label extension period (-9·8 [8·1] at month 18). Participants assigned placebo had a mean improvement from baseline in mRSS at 12 months (-3·7 [SD 7·6]), with a further improvement at month 18 (-6·3 [9·3]). Infections during the open-label extension phase occurred in nine patients in the placebo-abatacept group (12 adverse events, one serious adverse event) and in 11 patients in theabatacept-abatacept group (14 adverse events, one serious adverse event). Two deaths occurred during the 12-month double-blind period in the abatacept group, which were related to scleroderma renal crisis; no deaths were recorded during the open-label extension. INTERPRETATION: During the 6-month open-label extension, no new safety signals for abatacept were identified in the treatment of diffuse cutaneous systemic sclerosis. Clinically meaningful improvements in mRSS and other outcome measures were observed in both the abatacept and placebo groups when patients transitioned to open-label treatment. These data support further studies of abatacept in diffuse cutaneous systemic sclerosis. FUNDING: Bristol-Myers Squibb and National Institutes of Health.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chung L, Spino C, McLain R, et al. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol. 2020. PMID: 34966900. doi:10.1016/S2665-9913(20)30237-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。